Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
Rhea-AI Summary
Rein Therapeutics (NASDAQ: RNTX) priced an underwritten public offering of 50.0 million common shares at $1.00 per share for gross proceeds of $50 million, with a 45‑day option to purchase up to an additional 7.5 million shares. The offering is expected to close on or about May 4, 2026.
Rein intends to use net proceeds to fully fund its ongoing Phase 2 trial of LTI‑03 in idiopathic pulmonary fibrosis and for working capital; it believes proceeds plus cash on hand will fund operations into 2028.
Positive
- $50.0M gross proceeds from common stock offering
- Underwriting includes a 7.5M share over‑allotment option (45 days)
- Proceeds intended to fully fund Phase 2 LTI‑03 IPF trial
- Company projects cash runway into 2028
Negative
- Issuance of 50.0M new shares will dilute existing shareholders
- Potential additional dilution if underwriters exercise 7.5M option
- Offering priced at $1.00 per share, indicating low immediate per‑share proceeds
News Market Reaction – RNTX
In the May 1 session, RNTX declined 23.99%, reflecting a significant negative market reaction. Argus tracked a peak move of +3.0% during that session. Argus tracked a trough of -24.8% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Trial enrollment update | Positive | -12.1% | Phase 2 RENEW trial enrollment progress with new global sites planned. |
| Mar 03 | First patient dosed | Positive | -3.4% | First patient dosed in Phase 2 LTI-03 IPF trial after FDA clearance. |
| Jan 20 | EU orphan designation | Positive | -0.8% | European orphan drug designation granted for LTI-03 in IPF. |
| Nov 06 | Scientific publication | Positive | -1.9% | New preprint showing tolerability and fibrosis biomarker reductions for LTI-03. |
| Nov 03 | FDA trial clearance | Positive | +11.8% | FDA lifted full clinical hold on Phase 2 RENEW trial of LTI-03. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically focused headlines have mostly been positive in content but often saw negative price reactions, with only one clear alignment where strong regulatory news coincided with a price gain.
Over the past six months, Rein’s news flow has centered on LTI-03 for idiopathic pulmonary fibrosis. The company received FDA clearance to resume the Phase 2 RENEW trial and later reported new mechanistic data suggesting reduced lung scarring and biomarker improvements. It then secured European orphan drug designation and progressed into active Phase 2 dosing and enrollment updates through March–April 2026. Despite these generally constructive clinical and regulatory milestones, four of the last five news events saw negative next-day price moves, making today’s capital raise notable against a backdrop of mixed market reactions to prior positive updates.
Key Terms
underwritten public offering financial
over-allotments financial
idiopathic pulmonary fibrosis medical
Phase 2 clinical trial medical
registration statement on Form S-1 regulatory
prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of
Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC, is acting as the sole book-running manager for the offering.
Rein intends to use the net proceeds from the offering to fully fund its ongoing Phase 2 clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) through completion and for working capital and general corporate purposes. Based on its current operating plan, the Company believes the net proceeds from this offering, together with its existing cash and cash equivalents, will be sufficient to fund its operations into 2028.
The securities described above are being offered and sold pursuant to a registration statement on Form S-1 (File No. 333-295390), including a prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC"), which was declared effective by the SEC on April 30, 2026. The offering is being made only by means of a prospectus that forms part of the effective registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus may be obtained, when available, from Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC, at 7 World Trade Center, 46th Floor, New York, NY 10007, Attention: Capital Markets Team, Email: capmarkets@konikcapitalpartners.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. Rein’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements of Rein Therapeutics, Inc. (“Rein”, the “Company”, “we”, “our” or “us”) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to expectations for the Company’s LTI-03 and LTI-01 product candidates and the closing of the offering. We use words such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “would,” “can,” “could,” “should,” “continue,” and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: (i) the risk that the offering may not be completed, (ii) the risk that the net proceeds of the offering may not be sufficient to fund the Company’s operations into 2028, and (iii) those other risks disclosed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 26, 2026, and in subsequent filings that the Company makes with the SEC. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of this press release, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Rein Therapeutics Investor Relations & Media Contact:
Investor Relations
